These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 7614519)

  • 21. Evaluation of the effect of intravenous L-carnitine therapy on function, structure and fatty acid metabolism of skeletal muscle in patients receiving chronic hemodialysis.
    Siami G; Clinton ME; Mrak R; Griffis J; Stone W
    Nephron; 1991; 57(3):306-13. PubMed ID: 2017271
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of L-carnitine supplementation on lipid parameters in hemodialysis patients.
    Elisaf M; Bairaktari E; Katopodis K; Pappas M; Sferopoulos G; Tzallas C; Tsolas O; Siamopoulos KC
    Am J Nephrol; 1998; 18(5):416-21. PubMed ID: 9730566
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dramatic decrease of carnitine esters after interruption of exogenous carnitine supply in hemodialysis patients.
    Bene J; Csiky B; Wittmann I; Sulyok E; Melegh B
    Ren Fail; 2012; 34(5):555-8. PubMed ID: 22417076
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Carnitine metabolism in chronic kidney failure].
    Fiorini F; Patrone E; Castellucci A
    Clin Ter; 1992 Jan; 140(1 Pt 2):31-4. PubMed ID: 1559320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Oral carnitine supplementation for dyslipidemia in chronic hemodialysis patients.
    Naini AE; Sadeghi M; Mortazavi M; Moghadasi M; Harandi AA
    Saudi J Kidney Dis Transpl; 2012 May; 23(3):484-8. PubMed ID: 22569432
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of oral L-carnitine on serum myoglobin in hemodialysis patients.
    Feinfeld DA; Kurian P; Cheng JT; Dilimetin G; Arriola MR; Ward L; Manis T; Carvounis CP
    Ren Fail; 1996 Jan; 18(1):91-6. PubMed ID: 8820505
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of dialysate composition on the lipid response to L-carnitine supplementation.
    Zilleruelo G; Novak M; Hsia SL; Goldberg R; Abitbol C; Monkus E; Strauss J
    Kidney Int Suppl; 1989 Nov; 27():S259-63. PubMed ID: 2699997
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quality of life during and between hemodialysis treatments: role of L-carnitine supplementation.
    Sloan RS; Kastan B; Rice SI; Sallee CW; Yuenger NJ; Smith B; Ward RA; Brier ME; Golper TA
    Am J Kidney Dis; 1998 Aug; 32(2):265-72. PubMed ID: 9708611
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Oral carnitine therapy in children with cystinosis and renal Fanconi syndrome.
    Gahl WA; Bernardini I; Dalakas M; Rizzo WB; Harper GS; Hoeg JM; Hurko O; Bernar J
    J Clin Invest; 1988 Feb; 81(2):549-60. PubMed ID: 3276734
    [TBL] [Abstract][Full Text] [Related]  

  • 30. L-carnitine supplementation and adipokines in patients with end-stage renal disease on regular hemodialysis.
    Csiky B; Nyul Z; Tóth G; Wittmann I; Melegh B; Rauh M; Rascher W; Sulyok E
    Exp Clin Endocrinol Diabetes; 2010 Nov; 118(10):735-40. PubMed ID: 20658442
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Multiple-dose pharmacokinetics and bioequivalence of L-carnitine 330-mg tablet versus 1-g chewable tablet versus enteral solution in healthy adult male volunteers.
    Sahajwalla CG; Helton ED; Purich ED; Hoppel CL; Cabana BE
    J Pharm Sci; 1995 May; 84(5):627-33. PubMed ID: 7658356
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of L-carnitine pharmacokinetics with and without baseline correction following administration of single 20-mg/kg intravenous dose.
    Sahajwalla CG; Helton ED; Purich ED; Hoppel CL; Cabana BE
    J Pharm Sci; 1995 May; 84(5):634-9. PubMed ID: 7658357
    [TBL] [Abstract][Full Text] [Related]  

  • 33. L-carnitine supplementation decreases the left ventricular mass in patients undergoing hemodialysis.
    Sakurabayashi T; Miyazaki S; Yuasa Y; Sakai S; Suzuki M; Takahashi S; Hirasawa Y
    Circ J; 2008 Jun; 72(6):926-31. PubMed ID: 18503218
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Combined therapy with L-carnitine and erythropoietin of anemia in chronic kidney failure patients undergoing hemodialysis].
    Wanic-Kossowska M; Kazmierski M; Pawliczak E; Kobelski M
    Pol Arch Med Wewn; 2007; 117(1-2):14-9. PubMed ID: 17642201
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Influence of multiple-dose administration of cefetamet pivoxil on blood and urinary concentrations of carnitine and effects of simultaneous administration of carnitine with cefetamet pivoxil].
    Nakashima M; Kosuge K; Ishii I; Ohtsubo M
    Jpn J Antibiot; 1996 Oct; 49(10):966-79. PubMed ID: 8986559
    [TBL] [Abstract][Full Text] [Related]  

  • 36. L carnitine in hemodialysis patients.
    Calò LA; Vertolli U; Davis PA; Savica V
    Hemodial Int; 2012 Jul; 16(3):428-34. PubMed ID: 22360675
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aminoglycosides in intermittent hemodialysis: pharmacokinetics with individual dosing.
    Dager WE; King JH
    Ann Pharmacother; 2006 Jan; 40(1):9-14. PubMed ID: 16332944
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Plasma l-carnitine in patients with chronic hemodialysis. II. Pharmacokinetics of l-carnitine and its replacement therapy in these patients].
    Kudoh Y; Shoji T; Oimatsu H; Kikuchi K; Imura O; Watarai I
    Nihon Jinzo Gakkai Shi; 1984 Feb; 26(2):195-202. PubMed ID: 6748336
    [No Abstract]   [Full Text] [Related]  

  • 39. [L-carnitine in peritoneal dialysis].
    De Vecchi AF; Arduini A; Di Liberato L; Bonomini M
    G Ital Nefrol; 2011; 28(4):393-400. PubMed ID: 21809308
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Hemodialysis removal of propafenone.
    Burgess ED; Duff HJ
    Pharmacotherapy; 1989; 9(5):331-3. PubMed ID: 2813154
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.